Masahiro Kuno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masahiro Kuno has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Akira Ooki
Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
1 shared publication - Eiji Shinozaki
Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
1 shared publication - Hiroki Osumi
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan
1 shared publication - Junna Oba
The Ishii-Ishibashi Laboratory, Department of Extended Intelligence for Medicine, Graduate School of Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
1 shared publication - Kaoru Yoshikawa
Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
1 shared publication - Kazuhiro Sakurada
Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine and Graduate School of Medicine, Shinjuku, Japan
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 588
Artificial Intelligence in Clinical Oncology: From Productivity Enhancement to Creative Discovery
Modern clinical oncology faces an unprecedented data complexity that exceeds human analytical capacity, making artificial intelligence (AI) integration essential rather than optional. This review examines the dual impact of AI on productivity enhancement and creative discovery in cancer care. We trace the evolution from traditional machine learning to deep learning and transformer-based foundation models, analyzing their clinical applications. AI enhances productivity by automating diagnostic tasks, streamlining documentation, and accelerating research workflows across imaging modalities and clinical data processing. More importantly, AI enables creative discovery by integrating multimodal data to identify computational biomarkers, performing unsupervised phenotyping to reveal hidden patient subgroups, and accelerating drug development. Finally, we introduce the FUTURE-AI framework, outlining the essential requirements for translating AI models into clinical practice. This ensures the responsible deployment of AI, which augments rather than replaces clinical judgment, while maintaining patient-centered care.
- 22 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 588
Open AccessArtificial Intelligence in Clinical Oncology: From Productivity Enhancement to Creative Discovery
Modern clinical oncology faces an unprecedented data complexity that exceeds human analytical capacity, making artificial intelligence (AI) integration essential rather than optional. This review examines the dual impact of AI on productivity enhancement and creative discovery in cancer care. We trace the evolution from traditional machine learning to deep learning and transformer-based foundation models, analyzing their clinical applications. AI enhances productivity by automating diagnostic tasks, streamlining documentation, and accelerating research workflows across imaging modalities and clinical data processing. More importantly, AI enables creative discovery by integrating multimodal data to identify computational biomarkers, performing unsupervised phenotyping to reveal hidden patient subgroups, and accelerating drug development. Finally, we introduce the FUTURE-AI framework, outlining the essential requirements for translating AI models into clinical practice. This ensures the responsible deployment of AI, which augments rather than replaces clinical judgment, while maintaining patient-centered care.